Literature DB >> 2784101

Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor.

E M Cormier1, V C Jordan.   

Abstract

A potential mechanism is described by which a growth factor may prevent the action of antiestrogens or reactive the growth of hormone-responsive breast carcinoma in patients undergoing tamoxifen (TAM) treatment. Epidermal growth factor (EGF)-stimulated growth (10(-8) M EGF) was assayed in the MCF-7 breast cancer cell line in the presence of various concentrations (10(-10) to 10(-6) M) of three antiestrogens, 4-hydroxytamoxifen (OH TAM), TAM and ICI 164384. In each case, the EGF-stimulated increases in DNA were not inhibited by the antiestrogen. OH TAM and ICI 164384 inhibited estradiol (E2) stimulated cell proliferation in a dose-related fashion. However, in the presence of both E2 and EGF, these two antiestrogens inhibited E2 effects only; EGF promotion of growth was unaffected. Pretreatment of MCF-7 cells for 2 days with either OH TAM or ICI 164384 did not inhibit EGF-induced increases in cell proliferation. We propose that eventual antiestrogen therapeutic failure may be caused by the paracrine influences of growth factors from neighboring cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784101     DOI: 10.1016/0277-5379(89)90051-5

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  14 in total

1.  Influence of antiestrogens on EGF- and IGF-I-mediated proliferation of human breast cancer cells.

Authors:  G M Tong; T T Rajah; J T Pento
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-01       Impact factor: 2.416

2.  Antiestrogen inhibition of EGF-mediated invasiveness of human breast cancer cells.

Authors:  G M Tong; T T Rajah; X Zang; J T Pento
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-10       Impact factor: 2.416

3.  Quantification of the Effect of Toxicants on the Intracellular Kinetic Energy and Cross-Sectional Area of Mammary Epithelial Organoids by OCT Fluctuation Spectroscopy.

Authors:  Xiao Yu; Ashley M Fuller; Richard Blackmon; Melissa A Troester; Amy L Oldenburg
Journal:  Toxicol Sci       Date:  2018-03-01       Impact factor: 4.849

Review 4.  Antiestrogen action and growth factor regulation.

Authors:  L C Murphy
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

5.  The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture.

Authors:  V Craig Jordan
Journal:  Ann Surg Oncol       Date:  2019-03-25       Impact factor: 5.344

Review 6.  Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.

Authors:  V Craig Jordan; Joan Lewis-Wambi; Helen Kim; Heather Cunliffe; Eric Ariazi; Catherine G N Sharma; Heather A Shupp; Ramona Swaby
Journal:  Breast       Date:  2007-08-24       Impact factor: 4.380

7.  4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro.

Authors:  J N Sarkaria; E M Miller; C J Parker; V C Jordan; R T Mulcahy
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 8.  Autocrine growth factors and solid tumor malignancy.

Authors:  J H Walsh; W E Karnes; F Cuttitta; A Walker
Journal:  West J Med       Date:  1991-08

9.  The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis.

Authors:  Philipp Y Maximov; Joan S Lewis-Wambi; V Craig Jordan
Journal:  Curr Signal Transduct Ther       Date:  2009-05-01

10.  Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations.

Authors:  Elizabeth E Sweeney; Russell E McDaniel; Philipp Y Maximov; Ping Fan; V Craig Jordan
Journal:  Horm Mol Biol Clin Investig       Date:  2012-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.